Table 3.
Prognostic factors of progression free survival and overall survival
| Progression-free survival | Overall survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate Cox model | Multivariate Cox Model | Univariate Cox model | Multivariate Cox Model | |||||
| Variables | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI |
| FIGO | ||||||||
| IIB | 1.00 | 1.00 | ||||||
| IIIB | 1.22 | 0.72–2.07 | 1.03 | 0.57–1.88 | 2.03 | 0.87–4.73 | 1.69 | 0.64–4.53 |
| Differentiation degree | ||||||||
| Well | 1.00 | 1.00 | ||||||
| Moderately | 2.35 | 0.72–7.69 | 2.89 | 0.85–9.86 | 1.65 | 0.38–7.05 | 2.42 | 0.56–10.5 |
| Poorly | 1.78 | 0.45–7.03 | 1.83 | 0.46–7.50 | 0.92 | 0.15–0.56 | 0.95 | 0.15–5.70 |
| Treatment type | ||||||||
| Exclusive EBRT + Brachytherapy | 1.00 | 1.00 | ||||||
| Chemo-Radiotherapy + Brachytherapy | 0.58 | 0.35–0.95 | 0.57 | 0.32–1.00 | 0.38 | 0.18–0.80 | 0.36 | 0.16–0.82 |
| Tumor protein strong expression | ||||||||
| SURVIVIN | 1.02 | 0.46–2.28 | 1.37 | 0.51–3.67 | 1.35 | 0.40–4.47 | 1.80 | 0.51–6.46 |
| IGF1R-β | 1.53 | 0.81–2.89 | 1.81 | 0.87–3.76 | 2.7 | 0.94–7.73 | 5.38 | 1.59–18.3 |
| IGF1R-α | 1.07 | 0.57–1.98 | 1.08 | 0.54–2.17 | 1.58 | 0.60–4.12 | 2.06 | 0.70–6.12 |
| GLUT-1 | 0.99 | 0.54–1.83 | 1.04 | 0.55–1.98 | 1.66 | 0.77–3.55 | 2.22 | 0.99–5.04 |
| HIF-1α | 1.46 | 0.79–2.70 | 1.56 | 0.80–3.05 | 0.92 | 0.42–2.00 | 0.94 | 0.41–2.17 |
| CAIX | 0.52 | 0.20–1.32 | 0.50 | 0.20–0.30 | 0.53 | 0.16–1.77 | 0.58 | 0.17–2.02 |
| Impact of anemia | ||||||||
| Hb | 2.20 | 1.33–3.65 | 1.78 | 1.00–3.15 | 2.11 | 1.04–4.33 | 2.01 | 0.92–4.40 |
HR Hazard ratio, CI Confidence interval, FIGO International Federation of Gynecology and Obstetrics, EBRT External beam radiotherapy